Effects of kappa opioids on cocaine self-administration by rhesus monkeys

Journal of Pharmacology and Experimental Therapeutics

Volumn 282, Issue 1, 1997, Pages 44-55

  Negus, S Stevens ^a   Mello, Nancy K ^a   Portoghese, Philip S ^b   Lin, Chai En ^b  

^a MCLEAN HOSPITAL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; BENZOMORPHAN DERIVATIVE; BENZOMORPHAN ETHYLKETOCYCLAZOCINE; COCAINE; KAPPA OPIATE RECEPTOR AGONIST; KAPPA OPIATE RECEPTOR ANTAGONIST; NALOXONE; NORBINALTORPHIMINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DEPENDENCE; DRUG RECEPTOR BINDING; DRUG SELF ADMINISTRATION; DRUG TOLERANCE; FEMALE; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RHESUS MONKEY; SEDATION; VOMITING;

3,4-DICHLORO-N-METHYL-N-(2-(1-PYRROLIDINYL)-CYCLOHEXYL)-BENZENEACETAMIDE, (TRANS)-ISOMER; ANIMALS; CIRCADIAN RHYTHM; COCAINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHYLKETOCYCLAZOCINE; FEMALE; MACACA MULATTA; MALE; NALOXONE; NALTREXONE; PYRROLIDINES; RECEPTORS, OPIOID, KAPPA; SELF ADMINISTRATION; SUBSTANCE-RELATED DISORDERS;

EID: 0030759112     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (77)

1. BROADBEAR, J. H., NEGUS, S. S., BUTELMAN, E. R., DECOSTA, B. R. AND WOODS, J. H.: Differential effects of systemically administered nor-binaltorphimine (nor-BNI) on kappa-opioid agonists in the mouse writhing assay. Psychopharmacology 115: 311-319, 1994.
2. 2 analysis of the respiratory depressant effects of alfentanil, etonitazene, ethylketocyclazocine (EKC) and Mr2033 in rhesus monkeys. J. Pharmacol. Exp. Ther. 264: 145-151, 1993b.
3. BUTELMAN, E. R., NEGUS, S. S., AI, Y., DECOSTA, B. R. AND WOODS, J. H.: Kappa opioid antagonist effects of systemically administered nor-binaltorphimine in a thermal antinociception assay in rhesus monkeys. J. Pharmacol. Exp. Ther. 267: 1269-1276, 1993a.
4. BUTELMAN, E. R., FRANCE, C. P. AND WOODS, J. H.: Agonist and antagonist effects of dynorphin A-(1-13) in a thermal antinociception assay in rhesus monkeys. J. Pharmacol. Exp. Ther. 275: 374-380, 1995.
5. CHAVKIN, C., JAMES, I. F. AND GOLDSTEIN, A.: Dynorphin is a specific endogenous ligand of the opioid receptor. Science 215: 413-415, 1982.
6. CRAWFORD, C. A., MCDOUGALL, S. A., BOLANOS, C. A., HALL, S. AND BERGER, S. P.: The effects of the kappa agonist U-50,488 on cocaine-induced conditioned and unconditioned behaviors and Fos immunoreactivity. Psychopharmacology 120: 392-399, 1995.
7. DAUNAIS, J. B. AND MCGINTY, J. F.: Acute and chronic cocaine administration differentially alters striatal opioid and nuclear transcription factor mRNAs. Synapse 18: 35-45, 1994.
8. DAUNAIS, J. B. AND MCGINTY, J. F.: Cocaine binges differentially alter striatal preprodynorphin and zif/268 mRNAs. Mol. Brain Res. 29: 201-210, 1995.
9. DAUNAIS, J. B., ROBERTS, D. C. AND MCGINTY, J. F.: Short-term cocaine self-administration alters striatal gene expression. Brain Res. Bull. 37: 523-527, 1995.
10. DAVIS, R. E., CALLAHAN, M. J., DICKERSON, M. AND DOWNS, D. A.: Pharmacologic activity of CI-977, a selective kappa opioid agonist, in rhesus monkeys. J. Pharmacol. Exp. Ther. 261: 1044-1049, 1992.
11. DEVINE, D. P., LEONE, P., POCOCK, D. AND WISE, R. A.: Differential involvement of ventral tegmental mu, delta and kappa opioid receptors in modulation of basal mesolimbic dopamine release: in vivo microdialysis studies. J. Pharmacol. Exp. Ther. 266: 1236-1246, 1993.
12. DI CHIARA, G. AND IMPERATO, A.: Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J. Pharmacol. Exp. Ther. 244: 1067-1080, 1988.
13. DONZANTI, B. A., ALTHAUS, J. S., PAYSON, M. M. AND VONVOIGTLANDER, P. F.: Kappa agonist-induced reduction in dopamine release: site of action and tolerance. Res. Commun. Chem. Pathol. Pharmacol. 78: 193-210, 1992.
14. DYKSTRA, L. A., GMEREK, D. E., WINGER, G. AND WOODS, J. H.: Kappa opioids in rhesus monkeys. I. Diuresis, sedation, analgesia and discriminative stimulus effects. 242: 413-420, 1987a.
15. DYKSTRA, L. A., GMEREK, D. E., WINGER, G. AND WOODS, J. H.: Kappa opioids in rhesus monkeys. II. Analysis of the antagonistic actions of quadazocine and β-funaltrexamine. J. Pharmacol. Exp. Ther. 242: 421-427, 1987b.
16. EMMERSON, P. J., LIU, M-R., WOODS, J. H. AND MEDZIHRADSKY, F.: Binding affinity and selectivity of opioids at mu, delta and kappa receptors in monkey brain membranes. J. Pharmacol. Exp. Ther. 271: 1630-1637, 1994.
17. FRANCE, C. P., DE COSTA, B. R., JACOBSON, A. E., RICE, K. C. AND WOODS, J. H.: Apparent affinity of opioid antagonists in morphine-treated rhesus monkeys discriminating between saline and naltrexone. J. Pharmacol. Exp. Ther. 252: 600-604, 1990.
18. FRANCE, C. P., MEDZIHRADSKY, F. AND WOODS, J. H.: Comparison of kappa opioids in rhesus monkeys: Behavioral effects and receptor binding affinities. J. Pharmacol. Exp. Ther. 268: 47-58, 1994.
19. GLICK, S. D., MAISONNEUVE, I. M., RAUCCI, J. AND ARCHER, S.: Kappa opioid inhibition of morphine and cocaine self-administration in rats. Brain Res. 681: 147-152, 1995.
20. GMEREK, D. E., DYKSTRA, L. A. AND WOODS, J. H.: Kappa opioids in rhesus monkeys. III. Dependence associated with chronic administration. J. Pharmacol. Exp. Ther. 242: 428-436, 1987.
21. HANSON, G. R., SINGH, N., MERCHANT, K., JOHNSON, M. AND GIBB, J. W.: The role of NMDA receptor systems in neuropeptide responses to stimulants of abuse. Drug Alcohol Depend. 37: 107-110, 1995.
22. HEIDBREDER, C. A., BABOVIC-VUKSANOVIC, D., SHOAIB, M. AND SHIPPENBERG, T. S.: Development of behavioral sensitization to cocaine: Influence of kappa opioid receptor agonists. J. Pharmacol. Exp. Ther. 275: 150-163, 1995.
23. HOKFELT, T., VINCENT, S. R., DALSGAARD, C. J., HERRERA-MARSCHITZ, M., UNDERSTEDT, U., SCHULTZBERG, M., CHRISTENSSON, I. AND TERENIUS, L.: Some aspects on distribution and role of opioid peptides in the central and peripheral nervous system. In Central and Peripheral Endorphins: Basic and Clinical Aspects, ed. by E. E. Muller and A. R. Genazzani, pp. 1-16, Raven Press, New York, 1984.
24. HORAN, P., DE COSTA, B. R., RICE, K. C. AND PORRECA, F.: Differential antagonism of U69,593-and bremazocine-induced antinociception by (-)-UPHIT: evidence for kappa opioid receptor multiplicity in mice. J. Pharmacol. Exp. Ther. 257: 1154-1161, 1991.
25. HYMAN, S. E. AND NESTLER, E. J.: Initiation and adaptation: A Paradigm for understanding psychotropic drug action. Am. J. Psychiatry 153: 151-162, 1996.
26. HURD, Y. L. AND HERKENHAM, M.: Molecular alterations in the neostriatum of human cocaine addicts. Synapse 13: 357-369, 1993.
27. JOHANSON, C. E. AND FISCHMAN, M. W.: The pharmacology of cocaine related to its abuse. Pharmacol. Rev. 41: 3-52, 1989.
28. JONES, D. N. C. AND HOLTZMAN, S. G.: Long term κ-opioid receptor blockade following nor-binaltorphimine. Eur. J. Pharmacol. 215: 345-348, 1992.
29. KILLIAN, A. K., BONESE, K. AND SCHUSTER, C. R.: The effects of naloxone on behavior maintained by cocaine and heroin injections in the rhesus monkey. Drug Alcohol Depend. 3: 243-251, 1978.
30. KLEVEN, M. S. AND WOOLVERTON, W. L.: Effects of continuous infusions of SCH 23390 on cocaine-or food-maintained behavior in rhesus monkeys. Behav. Pharmacol. 1: 365-373, 1990.
31. KOE, B. K.: Molecular geometry of inhibitors of the uptake of catecholamines and serotonin in synaptosomal preparations of rat brain. J. Pharmacol. Exp. Ther. 199: 649-661, 1976.
32. KOOB, G. F. AND BLOOM, F. E.: Cellular and molecular mechanisms of drug dependence. Science. 242: 715-723, 1988.
33. KUHAR, M. J., RITZ, M. C. AND BOJA, J. W.: The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurosci. 14: 299-302, 1991.
34. KUMOR, K. M., HAERTZEN, C. A., JOHNSON, R. E., KOCHER, T. AND JASKINSKI, D.: Human psychopharmacology of ketocyclazocine as compared with cyclazocine, morphine and placebo. J. Pharmacol. Exp. Ther. 238: 960-968, 1986.
35. LINE, S. W., MARKOWITZ, H., MORGAN, K. N. AND STRONG, S.: Evaluation of attempts to enrich the environment of single-caged non-human primates. In Animal Care and Use in Behavioral Research: Regulations, Issues, and Applications, ed. by J. W. Driscoll, pp. 103-117, National Agricultural Library, Beltsville, MD, 1989.
36. LUKAS, S. E., MELLO, N. K., DRIEZE, J. M. AND MENDELSON, J. H.: Buprenorphine-induced alterations of cocaine's reinforcing properties in rhesus monkey: A dose-response analysis. Drug Alcohol Depend. 40: 87-98, 1995.
37. MAISONNEUVE, I. M., ARCHER, S. AND GLICK, S. D.: U50,488, a kappa opioid receptor agonist, attenuates cocaine-induced increases in extracellular dopamine in the nucleus accumbens of rats. Neurosci. Lett. 181: 57-60, 1994.
38. MANSOUR, A., Fox, C. A., BURKE, S., MENG, F., THOMPSON, R. C., AKIL, H. AND WATSON, S. J.: Mu, delta, and kappa opioid receptor mRNA expression in the rat CNS: An In Situ hybridization study. J. Comp. Neurol. 350: 412-138, 1994.
39. MANSOUR, A., KHACHATURIAN, H., LEWIS, M. E., AKIL, H. AND WATSON, S. J.: Autoradiographic differentiation of mu, delta, and kappa opioid receptors in the rat forebrain and midbrain. J. Neurosci. 7: 2445-2464, 1987.
40. MANSOUR, A., KHACHATURIAN, H., LEWIS, M. E., AKIL, H. AND WATSON, S. J.: Anatomy of CNS opioid receptors. Trends Neurosci. 7: 308-314, 1988.
41. MARTIN, W. R., EADES, C. G., THOMPSON, J. A., HUPPLER, R. E. AND GILBERT, P. E.: The effects of morphine-and nalorphine-like drugs in the non-dependent and morphine-dependent dog. J. Pharmacol. Exp. Ther. 197: 517-532, 1976.
42. MARTIN, W. R., FRASER, H. F., GORODETZKY, C. W. AND ROSENBERG, D. E.: Studies of the dependence-producing potential of the narcotic antagonists 2-cyclopropylmethyl 2′-hydroxy-5,9-dimethyl-6,7-benzomorphan (cyclazocine, Win 20,740, ARC 11-C-3). J. Pharmacol. Exp. Ther. 150: 426-436, 1965.
43. MARTIN, W. R., GORODETZKY, C. W. AND MCCLANE, T. K.: An experimental study in the treatment of narcotic addicts with cyclazocine. Clin. Pharmacol. Ther. 7: 455-464, 1966.
44. MELLO N. K., KAMIEN J. B., LUKAS S. E., DRIEZE J. AND MENDELSON J. H.: The effects of nalbuphine and butorphanol treatment on cocaine and food self-administration by rhesus monkeys. Neuropsychopharmacology 8: 45-55, 1993a.
45. MELLO N. K., LUKAS S. E., KAMIEN J. B., MENDELSON J. H. AND CONE E. J.: The effects of chronic buprenorphine treatment on cocaine and food self-administration by rhesus monkeys. J. Pharmacol. Exp. Ther. 260: 1185-1193, 1992.
46. MELLO N. K., KAMIEN J. B., LUKAS S. E., DRIEZE J. AND MENDELSON J. H.: Effects of intermittent buprenorphine administration on cocaine self-administration by rhesus monkeys. J. Pharmacol. Exp. Ther. 264: 530-541, 1993b.
47. MELLO N. K., MENDELSON J. H., BREE M. P. AND LUKAS S. E.: Buprenorphine suppresses cocaine self-administration by rhesus monkeys. Science 245: 859-862, 1989.
48. MELLO N. K., MENDELSON J. H., BREE M. P. AND LUKAS S. E.: Buprenorphine and naltrexone effects on cocaine self-administration by rhesus monkey. J. Pharmacol. Exp. Ther. 254: 926-939, 1990.
49. MELLO, N. K. AND NEGUS, S. S.: Preclinical evaluation of pharmacotherapies for treatment of cocaine and opiate abuse using drug self-administration procedures. Neuropsychopharmacology 14: 375-424, 1996.
50. MORRISON, D. F.: Multivariate Statistical Methods, McGraw-Hill, New York, 1990.
51. NATIONAL INSTITUTES OF HEALTH: Epidemiologic Trends in Drug Abuse. Community Epidemiology Work Group June 1996. Volume I: Highlights and executive summary. NIH Publication 96-4126, 1996.
52. NEGUS, S. S., MELLO, N. K., LAMAS, X. AND MENDELSON, J. H.: Acute and chronic effects of flupenthixol on the discriminative stimulus and reinforcing effects of cocaine in rhesus monkeys. J. Pharmacol. Exp. Ther. 278: 879-890, 1996.
53. NEGUS, S. S., MELLO, N. K., LUKAS, S. E. AND MENDELSON, J. H.: Diurnal patterns of cocaine and heroin self-administration in rhesus monkeys responding under a schedule of multiple daily sessions. Behav. Pharmacol. 6: 763-775, 1995b.
54. NEGUS, S. S., MELLO, N. K., PORTOGHESE, P. S., LUKAS, S. E. AND MENDELSON, J. H.: Role of delta opioid receptors in the reinforcing and discriminative stimulus effects of cocaine in rhesus monkeys. J. Pharmacol. Exp. Ther. 273: 1245-1256, 1995a.
55. NOCK, B., GIORDANO, A. L., CICERO, T. J. AND O'CONNOR, L. H.: Affinity of drugs and peptides for U69,593-sensitive and -insensitive kappa opiate binding sites: The U69,593-insensitive site appears to be the beta endorphin specific epsilon receptor. J. Pharmacol. Exp. Ther. 254: 412-419, 1990.
56. PFEIFFER, A., BRANT, V., HERZ, A. AND EMRICH, H. M.: Psychotomimesis mediated by opiate receptors. Science 233: 774-776, 1986.
57. PORTOGHESE, P. S., LIPKOWSKI, A. W. AND TAKEMORI, A. E.: Binaltorphimine and nor-binaltorphimine, potent and selective k-opioid receptor antagonists. Life Sci. 40: 1287-1292, 1987.
58. REECE, P. A., SEDMAN, A. J., ROSE, S., WRIGHT, D. S., DAWKINS, R. AND RAJAGOPALAN, R.: Diuretic effects, pharmacokinetics, and safety of a new centrally acting kappa-opioid agonist (CI-977) in humans. J. Clin. Pharmacol. 34: 1126-1132, 1994.
59. REITH, M. E. A.: Cocaine receptors on monoamine transporters and sodium channels. In Mechanisms of Cocaine Abuse and Toxicity, ed. by D. Clouet, K. Asghar and R. Brown, pp. 23-43, NIDA Research Monograph 88, Rockville, MD, 1988.
60. RIMOY, G. H., BHASKAR, N. K., WRIGHT, D. M. AND RUBIN, P. C.: Mechanism of diuretic action of spiradoline (U-62066E)-a kappa opioid receptor agonist in the human. Br. J. Clin. Pharmacol. 32: 611-615, 1991.
61. RITZ, M. C., LAMB, R. J., GOLDBERG, S. R. AND KUHAR, M. J.: Cocaine receptors in dopamine transporters are related to self-administration of cocaine. Science. 237: 1219-1223, 1987.
62. ROTHMAN, R. B., BYKOV, V., DE COSTA B. R., JACOBSON, A. E., RICE, K. C. AND BRADY, L. S.: Interaction of endogenous opioid peptides and other drugs with four kappa opioid binding sites in guinea pig brain. Peptides 11: 311-331, 1990.
63. SHIPPENBERG, T. S., LEFEVOUR, A. AND HEIDBREDER, C. A.: κ-opioid receptor agonists prevent sensitization to the conditioned rewarding effects of cocaine. J. Pharmacol. Exp. Ther. 276: 545-554, 1996.
64. SPANAGEL, R., HERZ, A. AND SHIPPENBERG, T. S.: Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc. Natl. Acad. Sci. U.S.A. 89: 2046-2050, 1992.
65. SPEALMAN, R. D. AND BERGMAN, J.: Modulation of the discriminative stimulus effects of cocaine by mu and kappa opioids. J. Pharmacol. Exp. Ther. 261: 607-615, 1992.
66. SPEALMAN, R. D. AND BERGMAN, J.: Opioid modulation of the discriminative stimulus effects of cocaine: Comparison of μ, k and ∂ agonists in squirrel monkeys discriminating low doses of cocaine. Behav. Pharmacol. 5: 21-31, 1994.
67. STEINER, H. AND GERFEN, C. R.: Dynorphin opioid inhibition of cocaine-induced, D1 dopamine receptor-mediated immediate-early gene expression in the striatum. J. Comp. Neurol. 353: 200-212, 1995.
68. SU, T.-P.: Further demonstration of kappa opioid binding sites in the brain: evidence for heterogeneity. J. Pharmacol. Exp. Ther. 232: 144-148, 1985.
69. SUZUKI, T., SHIOZAKI, Y., MASUKAWA, Y., MISAWA, M. AND NAGASE, H.: The role of mu-and kappa-opioid receptors in cocaine-induced conditioned place preference. Jpn. J. Pharmacol. 58: 435-442, 1992.
70. TAKEMORI, A. E., SCHWARTZ, M. M. AND PORTOGHESE, P. S.: Suppression by nor-binaltorphimine of kappa opioid-mediated diuresis in rats. J. Pharmacol. Exp. Ther. 247: 971-974, 1988.
71. TAYLOR, D. AND Ho, B. T.: Comparison of inhibition of monoamine uptake by cocaine, methylphenidate and amphetamine. Res. Commun. Chem. Pathol. Pharmacol. 21: 67-75, 1978.
72. UKAI, M., MIZUTANI, M. AND KAMEYAMA, T.: Opioid peptides selective for receptor types modulate cocaine-induced behavioral responses in mice. Yakubutsu Seishin Kodo 14: 153-159, 1994.
73. UNTERWALD, E. M., RUBENFELD, J. M. AND KREEK, M. J.: Repeated cocaine administration upregulates kappa and mu, but not delta, opioid receptors. Neuroreport. 5: 1613-1616, 1994.
74. VONVOIGTLANDER, P. F., LAHTI, R. A. AND LUDENS, J. H.: U-50,488: A selective and structurally novel non-mu (kappa) opioid agonist. J. Pharmacol. Exp. Ther. 224: 7-12, 1983.
75. WOODS, J. H. AND SCHUSTER, C. R.: Opiates as reinforcing stimuli. In Stimulus Properties of Drugs, ed. by T. Thompson and R. Pickens, pp. 163-175, Apple-Century-Crofts, New York, 1971.
76. WOOLVERTON, W. L. AND JOHNSON, K. M.: Neurobiology of cocaine abuse. Trends Pharmacol Sci. 13: 193-200, 1992.
77. 2 opioid receptors. Proc. Nat. Acad. Sci. U.S.A. 85: 4061-4065, 1988.